AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Other Oncology medicines — US product sales by Year
Other Oncology medicines — US product sales ($M) ($M)
AstraZeneca Other Oncology medicines — US product sales: $9M in FY2025, down 50.0% from a year earlier.
Where the FY2025 figure comes from
“|| Other Oncology | 425 | (8) | (8) | 9 | (52) | 280 | (6) | (4) | 19 | (17) | (19) | 117 | (6) | (7)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Oncology medicines — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9 | -50.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 18 | +200.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 6 | +500.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1 | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up other Oncology medicines — US product sales
Cite this data
StockData. (2026). AstraZeneca Other Oncology medicines — US product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-oncology-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.